Biopharmaceutical firm Atara Biotherapeutics has entered into a clinical trial collaboration agreement with Merck to evaluate the combination of its ATA129 with Keytruda (pembrolizumab) for the treatment of patients with nasopharyngeal carcinoma (NPC) associated with Epstein-Barr virus (EBV).

ATA129 is an investigational, allogeneic EBV-specific cytotoxic T-lymphocytes (CTL), while Merck's Keytruda is an anti-programmed death receptor-1 (anti-PD-1) therapy.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ATA129 + Keytruda will be assessed in a Phase I/II trial set to begin next year.

Under the agreement, Atara Bio will sponsor the trial, which will include patients with platinum-resistant or recurrent EBV-associated NPC.

"The investigational therapy was previously assessed in Phase I and II trials as a monotherapy in patients with various EBV-positive malignancies."

Atara Bio chief scientific officer and research and development executive vice-president Chris Haqq said: “Both ATA129 and Keytruda have shown evidence of objective radiographic responses in NPC, and there is a strong biologic rationale to combine these therapies as their complementary mechanisms of action may enhance the anti-tumour activity."

See Also:

ATA129 induces T-cells to identify EBV antigens that are expressed in the cells of some liquid and solid tumours.

The investigational therapy was previously assessed in Phase I and II trials as a monotherapy in patients with various EBV-positive malignancies.

The trial also included 14 patients with chemotherapy refractory, metastatic NPC and showed that EBV-CTLs expanded after treatment and without the associated lympho-depleting chemotherapy.

According to the data from recent studies, EBV upregulates PD-L1 transcription in related solid tumours such as NPC and gastric cancer, which provides scope for combination with anti-PD-1 therapies.